A Mother's Son
Clinical trials make the case for gene therapy injections in LHON patients
Phoebe Harkin | | Longer Read
Leber’s hereditary optic neuropathy (LHON) is a maternally inherited disorder caused by a point mutation in the mitochondrial DNA. It most often presents with rapid sequential bilateral loss of vision over weeks to months, with the second eye involved in 97 percent of patients by one year from onset. Patients are typically between 15 and 35 years of age, and 80 percent are men. Over 90 percent of patients are left legally blind, with less than 20/200 vision. The most common mutation in LHON patients is at the 11,778 position of the mitochondrial genome in the ND4 gene, accounting for 70 percent of patients.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.